These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 22074421)
21. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients]. Hironishi M; Miwa H; Kondo T No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758 [TBL] [Abstract][Full Text] [Related]
22. L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room. Paul R; Borah A Biochim Biophys Acta; 2016 Sep; 1860(9):1989-97. PubMed ID: 27318154 [TBL] [Abstract][Full Text] [Related]
23. Levodopa therapy for Parkinson's disease: Pharmacokinetics and pharmacodynamics. LeWitt PA Mov Disord; 2015 Jan; 30(1):64-72. PubMed ID: 25449210 [TBL] [Abstract][Full Text] [Related]
24. Microbial endocrinology as a basis for improved L-DOPA bioavailability in Parkinson's patients treated for Helicobacter pylori. Lyte M Med Hypotheses; 2010 May; 74(5):895-7. PubMed ID: 19962247 [TBL] [Abstract][Full Text] [Related]
25. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. LeWitt PA; Huff FJ; Hauser RA; Chen D; Lissin D; Zomorodi K; Cundy KC Mov Disord; 2014 Jan; 29(1):75-82. PubMed ID: 24339234 [TBL] [Abstract][Full Text] [Related]
26. Half a century of L-DOPA. Mena MA; Casarejos MJ; Solano RM; de Yébenes JG Curr Top Med Chem; 2009; 9(10):880-93. PubMed ID: 19754400 [TBL] [Abstract][Full Text] [Related]
27. Dilemma in the treatment of Parkinson's disease with L-dopa. Kuno S Eur Neurol; 1994; 34 Suppl 3():17-9. PubMed ID: 7821330 [TBL] [Abstract][Full Text] [Related]
28. L-dopa therapy for Parkinson's disease: past, present, and future. Nagatsua T; Sawadab M Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S3-8. PubMed ID: 19131039 [TBL] [Abstract][Full Text] [Related]
30. L-dopa-carbidopa: combined therapy for the treatment of Parkinson's disease. Celesia GG; Wanamaker WM Dis Nerv Syst; 1976 Mar; 37(3):123-5. PubMed ID: 1253661 [TBL] [Abstract][Full Text] [Related]
31. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304 [TBL] [Abstract][Full Text] [Related]
32. Gastroretentive carbidopa/levodopa, DM-1992, for the treatment of advanced Parkinson's disease. Verhagen Metman L; Stover N; Chen C; Cowles VE; Sweeney M Mov Disord; 2015 Aug; 30(9):1222-8. PubMed ID: 25847690 [TBL] [Abstract][Full Text] [Related]
33. Increased neostriatal dopamine activity after intraperitoneal or intranasal administration of L-DOPA: on the role of benserazide pretreatment. Silva MA; Mattern C; Häcker R; Tomaz C; Huston JP; Schwarting RK Synapse; 1997 Dec; 27(4):294-302. PubMed ID: 9372552 [TBL] [Abstract][Full Text] [Related]
34. Potential transbuccal delivery of l-DOPA methylester prodrug: stability in the environment of the oral cavity and ability to cross the mucosal tissue. Scaturro AL; De Caro V; Campisi G; Giannola LI Drug Deliv; 2016 Sep; 23(7):2355-2362. PubMed ID: 25533875 [TBL] [Abstract][Full Text] [Related]
35. Parkinson's Disease: Recent Updates in the Identification of Human Dopa Decarboxylase Inhibitors. Montioli R; Voltattorni CB; Bertoldi M Curr Drug Metab; 2016; 17(5):513-8. PubMed ID: 27025882 [TBL] [Abstract][Full Text] [Related]
36. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease. Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615 [TBL] [Abstract][Full Text] [Related]
37. DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease. Johnston TH; Versi E; Howson PA; Ravenscroft P; Fox SH; Hill MP; Reidenberg BE; Corey R; Brotchie JM Neuropharmacology; 2018 Mar; 131():116-127. PubMed ID: 29197517 [TBL] [Abstract][Full Text] [Related]